Unlike classical HLA class I molecules, seven HLA-G isoforms including four membrane-bound (HLA-G1-G4) and three soluble HLA-G isoforms (HLA-G5-G7) are generated by alternative splicing its primary transcripts
. Additionally, another soluble form of HLA-G molecule could be generated by shedding of the proteolytically cleaved surface HLA-G1 (sHLA-G1) [12] . Both [14] . [16] [17] [18] [19] [20] [21] [22] . Importantly, an increasing number of studies have highlighted the clinical relevance of HLA-G expression in cancer. Since Paul et al. [23] described the expression of HLA-G in melanoma for the first time, augmented HLA-G expression in situ was observed in nearly 20 types of tumours. HLA-G was preferentially detected in the tumour tissue and only rarely in the adjacent normal tissue, suggesting its specific association with tumour growth and progression [24, 25] . 
Apart from initially addressed in development of foetal maternal tolerance during pregnancy, clinical implication of HLA-G has been involved in a broad spectrum of physio-pathological situations [15]. In normal conditions, HLA-G is expressed in foetal trophoblast cells, and in other tissues such as adult thymic medulla, cornea, nail matrix, pancreatic islets, erythroid and endothelial precursors, and mesenchymal stem cells

To date, little information was available for the clinical relevance of HLA-G expression in hepatocellular carcinoma (HCC). In this study, HLA-G expression in primary HCC lesions was analysed, and its correlation to clinical parameters was evaluated. Furthermore, functions of transfected HLA-G expression in HCC cell line Hep-G2 on NK cell cytolysis were also analysed.
Materials and methods
Patients and specimens
HLA-G transfection of the HCC cell line Hep-G2
The Fig. 5B and C) . [31] . [32] [33] [34] , ovarian carcinoma [29, 35] , acute myeloid leukaemia [36] . Furthermore [38, 39] . Similar discrepancy remains in the studies on NSCLC. A recent report showed that HLA-G expression was observed in 75.0% (79/106) of the lesions analysed, whereas only 24.2% (8/33) was detectable in another study [37, 40] . For the controversial, in immunohistochemistry or in flow cytometry, FcR mediated binding of anti-HLA-G antibodies by macrophages might be a major problem, and all HLA I molecules share 80% amino acid sequence identity in their extracellular domain, cross-reactivity to other HLA I molecules by mAbs to HLA-G is possible [41, 42] [32, 33, 37, 44] [12, 45] . High serum sHLA-G level in neuroblastoma patients was found to be strongly correlated with relapse, and glioblastoma multiforme patients with high plasma sHLA-G levels had a significantly shorter survival than those with low sHLA-G levels [48, 50] [54] . The restoration of NK cell cytolysis was also observed in our previous studies on ovarian cancer and acute myeloid leukaemia when HLA-G was blocked by HLA-G specific mAb 87G [29, 36] . Taken 
Results
HLA-G expression in primary HCC lesions
Fig. 1 (A) Immunohistochemical detection of HLA-G expression in normal liver tissue and in primary HCC lesions. (A) Normal liver tissue is HLA-G -; (B) A representative of HCC lesion with HLA-G -; (C, D) A representative of HLA-G ϩ HCC lesions. HLA-G mAb 4H84 (1:300) was used to detect the HLA-G expression. Original magnification: 200ϫ. (B) Western blot analysis of HLA-G expression in HCC lesions. Two normal liver tissues and eighteen primary HCC lesions were analysed with Western blot. The degree of HLA-G expression was shown in brackets according to the case-matched immunohistochemistry data. JEG-3 and JAR lysates were used as HLA-G
Discussion
Loss or down-regulation of HLA class I molecules has been thought to be one of critical tumour escape mechanisms by circumventing antigen-specific T-cell response [2]. Lacking HLA class I molecules should render the tumour cells be susceptible to elimination by NK cells. However, tumour cells continue to grow and are not being efficiently destroyed by NK cells [3]. It is common that, during tumour development, tumour-specific and micro-environment cues induced antigen expression could be modulated on tumour cells. Among them, HLA-G is one of important antigens whose expression could be induced and provides immunoinhibitory effects on immune competent cells, and its aberrant expression in malignant cells may represent one of the various mechanisms used by the tumour cells to escape
Since the first address of HLA-G expression by tumour cells in 1998, numerous studies have been performed and HLA-G in situ expression was observed in various malignancies, such as oesophageal squamous cell carcinoma, colorectal cancer, retinoblastoma
. The only unambiguous means of detecting HLA-G expression is to identify the 39-kD heavy chain of HLA-G, which is distinct from the 45-kD classical
Fig. 4 Expression of transfected HLA-G on HCC cell line Hep-G2. (A) Flow cytometry analysis of cell surface HLA-G expression on Hep-G2 and Hep-G2-G cells with mAb MEM-G/9; HLA I expression was detected with mAb W6/32, and an appropriate isotope IgG1 was used as a control. (B) Western blot analysis of HLA-G expression in Hep-G2 and Hep-G2-G cells with mAb 4H84 (1:1000, Exbio
